姓名：李文芳

职称/职务：副教授，硕导

研究方向：肿瘤分子药理学、老药新用、新药临床前药理毒理研究。主要考察肿瘤抑制因子p53的网络调控机制及肿瘤干细胞的干性维持调控等方面的肿瘤研究；基于新的分子信号机制和新分子靶标开展小分子化合物在肿瘤治疗方面的分子生物医药转化应用研究。

邮箱：liwenfang@xju.edu.cn

办公室：太阳集团官网博达校区太阳成集团tyc151cc423室

个人经历

学习经历：

2018.09-2023.09重庆大学,生物医学工程,博士

2015.09-2018.06沈阳药科大学,药理学,硕士

2011.09-2015.06沈阳药科大学,药学/国际经济与贸易(药学方向)本科(双学位)

工作经历：

2023.10-至今太阳集团官网，药物研究所

2018.06-2018.09科伦药物研究院,药理毒理研究

主讲课程

本科生：专业英语、药理学、肿瘤生物学、生物化学、制药过程安全与环保、项目管理与技术经济

研究生：高级生物化学、专业英语

科研项目

2024年自治区天池博士计划，主持

国家自然科学基金委员会,面上项目, 32471260, MdmX促进非小细胞肺癌Mdm2抑制剂获得性耐药作用机理及其结构生物学机制研究, 2025-01-01至2028-12-31, 50万元,在研,参与

国家自然科学基金委员会,面上项目, 82173029,转录因子YY2通过调控线粒体分裂影响肿瘤干细胞不对称分裂的作用机制研究, 2022-01-01至2025-12-31, 54.7万元,在研,参与

社会工作

Cancer science、International Journal of Molecular Sciences、BIOMED PHARMACOTHER等审稿人

代表性研究成果

[1]Wenfang Li,Can Huang, Yu Tang, Li Qiu, Xia Zhang, Lei Zhang, Hezhao Zhao, Makoto Miyagishi, Shourong Wu, Vivi Kasim.p52-ZER6/IGF1R axis maintains cancer stem cell population to promote cancer progression by enhancing cell mitophagy.Oncogene43, 2115–2131 (2024).

[2]Wenfang Li, Leader Alfason, Can Huang, Yu Tang, Li Qiu, Makoto Miyagishi, Shourong Wu, Vivi Kasim. p52-ZER6: a determinant of tumor cell sensitivity to MDM2-p53 binding inhibitors.Acta Pharmacol Sin, 2023; 44, 647–660.

[3]Wenfang Li,Arin Herkilini, Yu Tang, Ping Huang, Guanbin Song, Makoto Miyagishi, Vivi Kasim, Shourong Wu. The transcription factor PBX3 promotes tumor cell growth through transcriptional suppression of the tumor suppressor p53.Acta Pharmacol Sin, 2021; 42, 1888–1899.

[4]Wenfang Li, Han Zhang,Jianxiong Xu,Ayitila Maimaitijiang,Zhengding Su,Zhongxiong FanandJinyao Li,The Biological Roles of ZKSCAN3 (ZNF306) in the Hallmarks of Cancer: From Mechanisms to Therapeutics.Int. J. Mol. Sci.2024, 25(21), 11532.

[5]Yu Tang,Wenfang Li（共同一作）,Li Qiu, Xia Zhang, Lei Zhang, Makoto Miyagishi, Hezhao Zhao, Shourong Wu, Vivi Kasim. The p52-ZER6/G6PD axis alters aerobic glycolysis and promotes tumor progression by activating the pentose phosphate pathway.Oncogenesis, 2023; 12, 17.

[6]Leader Alfason,Wenfang Li（共同一作）, Farwa Altaf, Shourong Wu, Vivi Kasim. Resuscitating the guardian: current progress in p53-based therapy.Onco Therapeutics,2021; 220, 107720.

[7]Ke Lei,Wenfang Li（共同一作）, Can Huang, Yanjun Li, Leader Alfason, Hezhao Zhao, Makoto Miyagishi, Shourong Wu, Vivi Kasim. Neurogenic differentiation factor 1 promotes colorectal cancer cell proliferation and tumorigenesis by suppressing the p53/p21 axis.Cancer Science, 2020; 111, 175–185.

[8]Han, Zhang., Jianxiong, Xu., Yuxuan, Long., Ayitila, Maimaitijiang., Zhengding, Su.,Wenfang, Li.（共同通讯）, Jinyao, Li.(2024). Unraveling the Guardian: p53's Multifaceted Role in the DNA Damage Response and Tumor Treatment Strategies.Int. J. Mol. Sci.2024, 25(23), 12928

[9]张涵,李文芳（通讯作者）.基于p53蛋白的抗肿瘤治疗策略研究进展[J].国际生物医学工程杂志,2024,47(05)：504-512.DOI:10.3760/cma.j.cn121382-20240822-00514.

[10]Li Qiu,Wenfang Li, Lei Zhang,Xia Zhang,Hezhao Zhao,Makoto Miyagishi, Shourong Wu, Vivi Kasim.p52-ZER6/DAZAP1 axis promotes ferroptosis resistance and colorectal cancer progression via regulating SLC7A11 mRNA stabilization.Acta Pharmaceutica Sinica B (In press).

[11]Can Huang, Shourong Wu,Wenfang Li, Arin Herkilini, Makoto Miyagishi, Hezhao Zhao, Vivi Kasim. Zinc-finger protein p52-ZER6 accelerates colorectal cancer cell proliferation and tumour progression through promoting p53 ubiquitination.EBioMedicine, 2019; 48, 248-263.

[12]Lei Zhang, Fuqiang Zhao,Wenfang Li, Guanbin Song,Vivi Kasim, Shourong Wu.The Biological Roles and Molecular Mechanisms of Long Non-Coding RNA MEG3 in the Hallmarks of Cancer.Cancers, 2022; 14, 6032.

[13]Xinxin Luo, Mankun Wei,Wenfang Li, Hezhao Zhao, Vivi Kasim, Shourong Wu. PBX3 promotes pentose phosphate pathway and colorectal cancer progression by enhancing G6PD expression.International Journal of Biological Sciences, 2023; 19(14), 4525-4538.

[14]Rendy, Hosea., Wei, Duan., Ian Timothy Sembiring, Meliala.,Wenfang Li, Mankun, Wei., Sharon, Hillary., Hezhao, Zhao., Makoto, Miyagishi., Shourong, Wu., Vivi, Kasim.(2024). YY2/BUB3 Axis promotes SAC Hyperactivation and Inhibits Colorectal Cancer Progression via Regulating Chromosomal Instability. Adv Sci (Weinh), 11(26), 0.

专利

(1)江启慧;吴寿荣;李文芳;黄灿;一种靶向肿瘤细胞的药物, 2019-10-12,中国,CN201910626900.X (专利)

(2)江启慧;吴寿荣;李文芳;黄灿;一种检测适用靶向p53的抗癌药的肿瘤患者的试剂盒, 2019-09-23,中国, CN201910626900.X(专利)